LC
CRNX icon

Lindbrook Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Lindbrook Capital’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$12.1K Buy
360
+23
+7% +$859 ﹤0.01% 1577
2024
Q4 		$17.2K Sell
337
-26
-7% -$1.46K ﹤0.01% 1366
2024
Q3 		$18.5K Buy
363
+9
+3% +$464 ﹤0.01% 1344
2024
Q2 		$15.9K Buy
354
+77
+28% +$3.56K ﹤0.01% 1380
2024
Q1 		$13K Buy
277
+244
+739% +$9.55K ﹤0.01% 1428
2023
Q4 		$1.17K Sell
33
-16
-33% -$491 ﹤0.01% 2434
2023
Q3 		$1.46K Buy
+49
New +$1.01K ﹤0.01% 2234
2022
Q4 		– Sell
-113
Closed -$2K – 2862
2022
Q3 		$2K Buy
113
+12
+12% +$245 ﹤0.01% 2024
2022
Q2 		$2K Buy
101
+67
+197% +$1.34K ﹤0.01% 1930
2022
Q1 		$1K Buy
+34
New +$688 ﹤0.01% 2194

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lindbrook Capital's CRNX Position: Q1 2025 in Review

Lindbrook Capital increased its Crinetics Pharmaceuticals (CRNX) stake by 6.8% in Q1 2025, buying an estimated $859 and bringing the position to 360 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1577.

Lindbrook Capital first reported a position in CRNX in Q1 2022 and has held it in 10 quarters since. The position peaked at $18.5K in Q3 2024. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

  • Lindbrook Capital held 360 shares of Crinetics Pharmaceuticals worth $12.1K as of Q1 2025.
  • Lindbrook Capital bought 23 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $859.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1577 holding.
  • Lindbrook Capital first reported a position in Crinetics Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
  • Lindbrook Capital's Crinetics Pharmaceuticals position peaked at $18.5K in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.